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An editorial about personalized medicine should per-
haps start with a definition. Although several versions of
such definition exist, we pay homage here to the oldest
definition reported in modern medical literature. Sir
William Osler (1849-1919) recognized that “variability is
the law of life, and as no two faces are the same, so no
two bodies are alike, and no two individuals react alike
and behave alike under the abnormal conditions we
know as disease”. Modern day medicine recognized this
fact and implemented its ethos since inception of its
practice separating it from a general “one-size-fits-all”
approach. A medical doctor would ask the patient about
his/her suffering and prescribe a treatment suited to the
patient’s condition. Individualized evaluation and treat-
ments, which include history taking, focused examina-
tion and specific laboratory and medical tests have now
become routine in day-to-day medical practice. Persona-
lized medicine, takes into account the needs of indivi-
dual patients, and provides custom-tailored therapeutic
approaches.
More recently, modifying life style approaches as part
of a broad preventive medicine orientation, are gaining
popularity and yielding positive results. Weight manage-
ment, smoking cessation and healthy diet are well-estab-
lished preventive strategies that have a contributed a
great deal in reducing mortality associated with chronic
diseases. But there are challenges. For example, losing
weight is easy. But, maintaining it at an optimum level
is a challenge!
Similarly, limits of existing diagnostic and therapeutic
strategies are becoming well-known. Despite all the
impressive advances in imaging technology, advent of
new medical diagnostics, and burgeoning of therapeutic
interventions, the widespread prevalence of disability
and premature mortality associated with chronic condi-
tions such as diabetes, cancer and heart disease
continues to frustrate scientists and clinicians alike.
There are also many unanswered questions. Here is one
such question. Why two patients with exactly the same
diagnosis and identical test results respond differently to
the same treatment.
Have we reached a glass ceiling? Are we limited in our
scientific understanding of disease and health? Rapid
advances in genotyping and genomics might shed some
light. Let us look at example of the oral anticoagulant
drug Warfarin that is used for the long-term manage-
ment of thromboembolic events. Studies have shown
that of over 21 million patients, who are on Warfarin in
the USA, some suffer from its adverse effects [1] and
others don’t. Why? Research has shown that there is a
variant nucleotide in the Cytochrome P450 CYP2C9,
which is responsible for this variation observed in the
drug response [2]. Other genetic variations that alter the
personal response to Warfarin also exist in the Vitamin
K epoxide reductase complex protein 1 (VKORC1) [3].
The U.S. Food and Drug Administration (FDA) has
recognized and acknowledged the importance of geno-
typing CYP2C9 and VKORC1 during Warfarin treat-
ment [4,5]. In doing so, it has given the field of
genomics a tremendous boost.
Let us take a look at another example. Trastuzumab is
a very effective drug for breast cancer treatment. How-
ever, only 10-20% of the breast cancer patients can ben-
efit from it. This is due to the fact that Trastuzumab is
based on monoclonal antibodies targeting the Epidermal
Growth Factor Receptor (HER2/neu/EGFR) [6]. There-
fore only patients with amplification (multiple copies) of
HER2/neu/EGFR will respond to this treatment. The
availability of Trastuzumab has created a research drive
at a frantic pace, to standardize the detection of HER2/
neu/EGFR amplification, for which several methods are
now available.
The utility of genomics in personalized medicine is
gaining popularity. Its potential for predicting disease
occurrence is receiving worldwide attention and illu-
strated by examining the relationship between certain
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allele’s and cancer risk. For example, the presence of
mutant BRCA1 or BRCA2 allele substantially increases
the risk of breast and/or ovarian cancer. Similarly, the
presence of certain variant single nucleotide polymorph-
isms (SNPs, e.g. FGFR2) also significantly escalates the
probability of developing breast cancer. Specific SNPs
have also been identified which are associated with
increased risk of diabetes, rheumatoid arthritis or
chronic heart disease as well as other multi-factorial dis-
eases. This list is continuously being updated as addi-
tional SNPs are being identified from a wide range of
promising genome-wide association studies, which are
underway throughout the world. Technology aimed at
predicting disease and health outcomes is gaining
momentum.
The promise of genomic evaluation as an integral
component of personalized medicine is fast becoming a
reality in many nations around the world. The recent
announcement of the formation of the Genomic Cancer
Care Alliance between one of the biggest providers of
next-generation sequencing solutions, Life Technologies,
and leading research centers such as Fox Chase Cancer
Center, Scripps Genomic Medicine, and the Transla-
tional Genomics Research Institute (TGen) is an illustra-
tion of that reality. The goal of this alliance is to launch
a pilot study aimed at determining whether whole-gen-
ome sequencing can positively affect the treatment deci-
sions across a number of cancers with limited treatment
options. Research laboratories with access to the high-
throughput sequencing technology are already imple-
menting Whole-Exome Seq in the identification of
genetic causes of congenital abnormalities, such as con-
genital hearing loss.
Current concept of ‘Personalized medicine’ approach
thus incorporates the traditional assessment methods,
genotyping, and genomic evaluation in predicting dis-
ease risk and treatment outcomes. Additionally, it
encourages patients to participate in their own care: par-
ticipative component of personalized medicine. Research
has shown that patients who participate in their own
care have better outcomes than patients who don’t [7].
Most health care ‘gurus’ agree that health care will
become more person-specific in its approach, and will
be driven by the patients’ felt needs, their perceptions
about health and disease and their behavior. Taking into
account the patient’s behavior and other factors sur-
rounding the doctor-patient relationship in managing
disease and illness is vital, and will become more impor-
tant in years ahead.
It is well known that human factors, which signifi-
cantly improve disease outcomes, are many [8]. Healing
words, pleasant environment, and family and social sup-
port, to name a few, are well known examples of such
factors. Patient feelings and attitudes also matter.
Positive attitude and feelings result in better outcomes.
Negative feelings and hopelessness, on the other hand,
can have detrimental effects. There is now evidence, for
example, that hopelessness accelerates carotid athero-
sclerosis [9].
Interaction between the doctor and the patient is vital
in the overall healing response. Empathy, caring and
helping patients cope with their suffering have a real
impact on patient outcomes.
There are many scientists who concur that many
human factors, placebo or context factors as some may
call them [8], described above may be operating via psy-
choneuroimmunology paradigm [10], which is “the com-
plex interrelationship between the mind or psychology,
the brain, the immune system and general health”. A
recent study showed an association between genetically
controlled amygdala activity and placebo-induced relief
from anxiety. This is a striking observation and will no
doubt lead to additional research initiatives on this sub-
ject [11] Soon, we will see scientists beginning to iden-
tify allele’s and SNP which guide human behavior and
factors (placebo and context effects). That information
could be immensely helpful in optimizing healing
responses in certain individuals.
The genomics technology is advancing at a rapid pace.
The cost of sequencing whole human genomes is now
within reach of most research laboratories. As the tech-
nology continues to grow and advance we need to be
mindful of the challenges and questions that the upcom-
ing discipline of ‘personalized medicine’ is likely to pre-
sent in times ahead. The key question for a health care
provider is who will pay the high for the use of persona-
lized genomics? In the U.S.A, medical insurance compa-
nies are so far resisting re-imbursements for routine
genetic testing delaying the implementation of persona-
lized medicine. It remains to be seen how such technol-
ogy will be paid for in other countries like the United
Kingdom where the health service is largely funded by
the public sector (National Health Service, NHS).
Here is another challenging question. How likely is it
that individual genome information may be used to dis-
criminate against people with negative health and perso-
nal traits? This could be a serious ethical issue that the
law and policy makers may have to grapple with in
times ahead. Protecting the confidentiality of the geno-
mic information will also be of concern.
Despite some of the concerns noted above, persona-
lized medicine is the way forward. It is a melding of tra-
ditional (e.g., personalized history, examination, and
laboratory tests) and novel approaches, e.g., genotyping,
genomic evaluations). It uses the science of prediction,
principles of modern therapeutics and prevention, and
optimizes active participation of patients in their own
care. Treating the patient as a person (with his/her
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human attributes) and not just their illness is also an
essential element of this approach. This wholesome and
person-centered approach to health care should improve
outcomes, reduce morbidity and mortality, and at the
same time alleviate pain and human suffering commonly
associated with chronic illnesses such as cancer and
heart disease.
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